Fatigue, Countermeasures, and Performance Enhancement in Resident Physicians

Rose, Steven H.; Curry, Timothy B.
March 2010
Mayo Clinic Proceedings;Mar2010, Vol. 85 Issue 3, p301
Academic Journal
A letter to the editor is presented concerning a study conducted by Steven Rose and Timothy Curry on the efficacy of the drug armodafinil in treating fatigue and lessening the risk of medical errors in resident physicians.


Related Articles

  • Wake-Promoting Therapeutic Medications Not an Appropriate Alternative to Implementation of Safer Work Schedules for Resident Physicians. Czeisler, Charles A. // Mayo Clinic Proceedings;Mar2010, Vol. 85 Issue 3, p302 

    A letter to the editor is presented concerning a randomized controlled study conducted by Steven Rose and Timothy Curry of the efficacy of the drug, armodafinil, in treating shift work disorder that was published in the November 2009 issue.

  • Putting Calcium Channels in Their Place. Ritter, Amy // BioPharm International;Jun2012, Vol. 25 Issue 6, p10 

    The article reports on a study which investigates the effectiveness of the painkiller Lyrica (pregabalin), which is approved for treating neuropathic pain, seizures, and fibromyalgia published online in the May 13, 2012 issue of "Nature."

  • Improving mental health symptoms for psoriasis patients.  // British Journal of Hospital Medicine (17508460);Jun2010, Vol. 71 Issue 6, p309 

    The article reports on the findings of a study which revealed the effectiveness of ustekinumab or Stelara drug to improve the mental health symptoms and quality of life of patients with psoriasis.

  • Treating Venous thromboembolism with rivaroxaban. Kuritzky, Louis // Internal Medicine Alert;2/28/2011 Supplement, p32 

    The article reports on a study which discovers the effectiveness of oral rivaroxaban in treating venous thromboembolism.

  • But Does It Work? Breindl, Anette // BioWorld Today;9/16/2013, Vol. 24 Issue 177, p1 

    The article offers brief information on the suggestions of researchers from Harvard Medical School in Massachusetts for new methods of evaluating cancer drug effectiveness by considering factors which unite drug efficacy and potency in a single parameter such as binding cooperativity and maximum...

  • The roots of resistance. Ledford, Heidi // Nature;11/25/2010, Vol. 468 Issue 7323, p490 

    The article presents studies which examine the failure of the cancer drug PLX4032 from Plexxikon for patients with melanoma in which the excessive production of a cancer-promotion protein called COT can protect cultured cells from the drug, and by reactivating the B-RAF signaling pathway and by...

  • New epilepsy treatments have had limited impact.  // Pulse;10/19/2011, Vol. 71 Issue 34, p15 

    The article focuses on the study conducted at the Western Infirmary Epilepsy Unit in Glasgow, Scotland between 2000 and 2010 which shows that anti-epileptic drugs have no substantial effect on preventing seizures.

  • Ruxolitinib extended OS in myelofibrosis. Leiser, Mark; Southall, Jennifer; Stott, Bob; Todak, Alexandra // Hem/Onc Today;1/25/2014, Vol. 15 Issue 2, p36 

    The article discusses the COMFORT-I and COMFORT-II placebo-controlled studies, which show the drug ruxolitinib's association with extended overall survival (OS) compared with placebo and other best available therapies in patients with intermediate- and high-risk myelofibrosis.

  • Caspofungin may be effective as pre-emptive strategy in ICU patients. Schoen, John; Shafer, Emily; Thiel, Bruce // Infectious Disease News;Mar2014, Vol. 27 Issue 3, p16 

    The article discusses research on the effects of caspofungin on invasive candidiasis, referencing a study by L. Ostrosky-Zeichner published in a 2014 issue of the journal "Clinical Infectious Diseases."


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics